{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T16:14:46Z","timestamp":1782836086180,"version":"3.54.5"},"reference-count":64,"publisher":"MDPI AG","issue":"20","license":[{"start":{"date-parts":[[2022,10,18]],"date-time":"2022-10-18T00:00:00Z","timestamp":1666051200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Medical University of Lublin, Poland","award":["GI\/3"],"award-info":[{"award-number":["GI\/3"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cells"],"abstract":"<jats:p>For many years, researchers have been trying to develop the most effective ways to fight lung cancer, which is the cause of the largest number of cancer-related deaths among men and women worldwide. The most advanced treatments for nearly all non-small-cell lung cancer (NSCLC) types include immunotherapy with immune checkpoint inhibitors (ICIs), mainly anti-programmed death 1\/anti-programmed death ligand 1 monoclonal antibodies (anti-PD-1\/PD-L1 mAbs) in monotherapy or in combination with other strategies. Despite significant advances, long survival is not achievable in most cases, so new solutions are constantly being sought. One of the questions raised by oncologists is the efficacy of ICIs in patients with molecular driver alterations, especially when the possibilities of using molecularly targeted therapies are exhausted (e.g., due to resistance to tyrosine kinase inhibitors). There are studies investigating this problem, but it is still poorly described. Among probable immunotherapy\u2019 failures reasons, low immunogenicity of tumors with one driver mutation is listed. Nevertheless, in some cases, the therapy is efficient, and more research is required to establish the management of NSCLC patients with oncogenic driver abnormalities. The aim of this article is to review current discoveries in this matter.<\/jats:p>","DOI":"10.3390\/cells11203280","type":"journal-article","created":{"date-parts":[[2022,10,18]],"date-time":"2022-10-18T21:18:02Z","timestamp":1666127882000},"page":"3280","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Immunotherapy in Non-Small-Cell Lung Cancer Patients with Driver Alterations: A New Strategy?"],"prefix":"10.3390","volume":"11","author":[{"given":"Natalia","family":"Krzy\u017canowska","sequence":"first","affiliation":[{"name":"Department of Pneumonology, Oncology and Allergology, Medical University of Lublin, 20-090 Lublin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pawe\u0142","family":"Krawczyk","sequence":"additional","affiliation":[{"name":"Department of Pneumonology, Oncology and Allergology, Medical University of Lublin, 20-090 Lublin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9947-5169","authenticated-orcid":false,"given":"Kamila","family":"Wojas-Krawczyk","sequence":"additional","affiliation":[{"name":"Department of Pneumonology, Oncology and Allergology, Medical University of Lublin, 20-090 Lublin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2678-8655","authenticated-orcid":false,"given":"Tomasz","family":"Kucharczyk","sequence":"additional","affiliation":[{"name":"Department of Pneumonology, Oncology and Allergology, Medical University of Lublin, 20-090 Lublin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janusz","family":"Milanowski","sequence":"additional","affiliation":[{"name":"Department of Pneumonology, Oncology and Allergology, Medical University of Lublin, 20-090 Lublin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,10,18]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"103119","DOI":"10.1016\/j.critrevonc.2020.103119","article-title":"Beyond EGFR, ALK and ROS1: Current Evidence and Future Perspectives on Newly Targetable Oncogenic Drivers in Lung Adenocarcinoma","volume":"156","author":"Lamberti","year":"2020","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21654","article-title":"Cancer Statistics, 2021","volume":"71","author":"Siegel","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"e216","DOI":"10.1016\/j.cllc.2019.12.003","article-title":"Tyrosine Kinase Inhibitors for the Treatment of EGFR Mutation-Positive Non\u2013Small-Cell Lung Cancer: A Clash of the Generations","volume":"21","author":"Shah","year":"2020","journal-title":"Clin. Lung Cancer"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/s41568-019-0179-8","article-title":"Co-Occurring Genomic Alterations in Non-Small Cell Lung Cancer and Therapy","volume":"19","author":"Skoulidis","year":"2019","journal-title":"Nat. Rev. Cancer"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Russell, M.C., Garelli, A.M., and Reeves, D.J. (2022). Targeting EGFR Exon 20 Insertion Mutation in Non-Small Cell Lung Cancer: Amivantamab and Mobocertinib. Ann. Pharmacother., 10600280221098398.","DOI":"10.1177\/10600280221098398"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"863461","DOI":"10.3389\/fonc.2022.863461","article-title":"Targeting ALK Rearrangements in NSCLC: Current State of the Art","volume":"12","author":"Peng","year":"2022","journal-title":"Front. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11912-021-01078-y","article-title":"ROS1 Targeted Therapies: Current Status","volume":"23","author":"Azelby","year":"2021","journal-title":"Curr. Oncol. Rep."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1634\/theoncologist.2017-0642","article-title":"FDA Approval Summary: Dabrafenib and Trametinib for the Treatment of Metastatic Non\u2013Small Cell Lung Cancers Harboring BRAF V600E Mutations","volume":"23","author":"Odogwu","year":"2018","journal-title":"Oncologist"},{"key":"ref_10","first-page":"418","article-title":"Larotrectinib and Entrectinib: TRK Inhibitors for the Treatment of Pediatric and Adult Patients with NTRK Gene Fusion","volume":"11","author":"Dunn","year":"2020","journal-title":"J. Adv. Pract. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Cascetta, P., Sforza, V., Manzo, A., Carillio, G., Palumbo, G., Esposito, G., Montanino, A., Costanzo, R., Sandomenico, C., and de Cecio, R. (2021). RET Inhibitors in Non-Small-Cell Lung Cancer. Cancers, 13.","DOI":"10.3390\/cancers13174415"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1158\/1078-0432.CCR-21-1566","article-title":"FDA Approval Summary: Capmatinib and Tepotinib for the Treatment of Metastatic NSCLC Harboring MET Exon 14 Skipping Mutations or Alterations","volume":"28","author":"Mathieu","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1158\/1078-0432.CCR-21-3074","article-title":"FDA Approval Summary: Sotorasib for KRAS G12C-Mutated Metastatic NSCLC","volume":"28","author":"Nakajima","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.path.2019.11.002","article-title":"Targeted Therapy and Checkpoint Immunotherapy in Lung Cancer","volume":"13","author":"Devine","year":"2020","journal-title":"Surg. Pathol. Clin."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus Docetaxel in Advanced Nonsquamous Non\u2013Small-Cell Lung Cancer","volume":"373","author":"Borghaei","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0140-6736(16)32517-X","article-title":"Atezolizumab versus Docetaxel in Patients with Previously Treated Non-Small-Cell Lung Cancer (OAK): A Phase 3, Open-Label, Multicentre Randomised Controlled Trial","volume":"389","author":"Rittmeyer","year":"2017","journal-title":"Lancet"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/S0140-6736(15)01281-7","article-title":"Pembrolizumab versus Docetaxel for Previously Treated, PD-L1-Positive, Advanced Non-Small-Cell Lung Cancer (KEYNOTE-010): A Randomised Controlled Trial","volume":"387","author":"Herbst","year":"2016","journal-title":"Lancet"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"3987","DOI":"10.1200\/JCO.2012.45.2029","article-title":"Emerging Paradigms in the Development of Resistance to Tyrosine Kinase Inhibitors in Lung Cancer","volume":"31","author":"Gainor","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1158\/2159-8290.CD-13-0310","article-title":"Activation of the PD-1 Pathway Contributes to Immune Escape in EGFR-Driven Lung Tumors","volume":"3","author":"Akbay","year":"2013","journal-title":"Cancer Discov."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Hong, S., Chen, N., Fang, W., Zhan, J., Liu, Q., Kang, S., He, X., Liu, L., Zhou, T., and Huang, J. (2016). Upregulation of PD-L1 by EML4-ALK Fusion Protein Mediates the Immune Escape in ALK Positive NSCLC: Implication for Optional Anti-PD-1\/PD-L1 Immune Therapy for ALK-TKIs Sensitive and Resistant NSCLC Patients. Oncoimmunology, 5.","DOI":"10.1080\/2162402X.2015.1094598"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1097\/JTO.0000000000000500","article-title":"Upregulation of PD-L1 by EGFR Activation Mediates the Immune Escape in EGFR-Driven NSCLC: Implication for Optional Immune Targeted Therapy for NSCLC Patients with EGFR Mutation","volume":"10","author":"Chen","year":"2015","journal-title":"J. Thorac. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1093\/annonc\/mdz167","article-title":"Immune Checkpoint Inhibitors for Patients with Advanced Lung Cancer and Oncogenic Driver Alterations: Results from the IMMUNOTARGET Registry","volume":"30","author":"Mazieres","year":"2019","journal-title":"Ann. Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"4585","DOI":"10.1158\/1078-0432.CCR-15-3101","article-title":"EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis","volume":"22","author":"Gainor","year":"2016","journal-title":"Clin. Cancer. Res."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1016\/j.jtho.2018.03.035","article-title":"A Phase II Study of Pembrolizumab in EGFR-Mutant, PD-L1+, Tyrosine Kinase Inhibitor (TKI) Na\u00efve Patients with Advanced NSCLC","volume":"13","author":"Lisberg","year":"2018","journal-title":"J. Thorac. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.jtho.2018.11.028","article-title":"Pembrolizumab in Combination with Erlotinib or Gefitinib as First-Line Therapy for Advanced NSCLC with Sensitizing EGFR Mutation","volume":"14","author":"Yang","year":"2019","journal-title":"J. Thorac. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/S1470-2045(18)30144-X","article-title":"Durvalumab as Third-Line or Later Treatment for Advanced Non-Small-Cell Lung Cancer (ATLANTIC): An Open-Label, Single-Arm, Phase 2 Study","volume":"19","author":"Garassino","year":"2018","journal-title":"Lancet Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.cllc.2020.12.015","article-title":"Subtypes of EGFR- and HER2-Mutant Metastatic NSCLC Influence Response to Immune Checkpoint Inhibitors","volume":"22","author":"Lau","year":"2021","journal-title":"Clin. Lung Cancer"},{"key":"ref_28","first-page":"100187","article-title":"Response to Immune Checkpoint Inhibition as Monotherapy or in Combination with Chemotherapy in Metastatic ROS1-Rearranged Lung Cancers","volume":"2","author":"Choudhury","year":"2021","journal-title":"JTO Clin. Res. Rep."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1158\/2159-8290.CD-18-0099","article-title":"STK11\/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma","volume":"8","author":"Skoulidis","year":"2018","journal-title":"Cancer Discov."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1016\/j.jtho.2018.04.024","article-title":"BRAF Mutant Lung Cancer: Programmed Death Ligand 1 Expression, Tumor Mutational Burden, Microsatellite Instability Status, and Response to Immune Check-Point Inhibitors","volume":"13","author":"Dudnik","year":"2018","journal-title":"J. Thorac. Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/j.jtho.2019.12.129","article-title":"Efficacy and Safety of Anti\u2013PD-1 Immunotherapy in Patients with Advanced NSCLC with BRAF, HER2, or MET Mutations or RET Translocation: GFPC 01-2018","volume":"15","author":"Guisier","year":"2020","journal-title":"J. Thorac. Oncol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1093\/annonc\/mdy334","article-title":"PD-L1 Expression, Tumor Mutational Burden, and Response to Immunotherapy in Patients with MET Exon 14 Altered Lung Cancers","volume":"29","author":"Sabari","year":"2018","journal-title":"Ann. Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.1016\/j.jtho.2021.06.025","article-title":"Efficacy of Immune Checkpoint Inhibitors Alone or in Combination with Chemotherapy in NSCLC Harboring ERBB2 Mutations","volume":"16","author":"Saalfeld","year":"2021","journal-title":"J. Thorac. Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Hegde, A., Andreev-Drakhlin, A.Y., Roszik, J., Huang, L., Liu, S., Hess, K., Cabanillas, M., Hu, M.I., Busaidy, N.L., and Sherman, S.I. (2020). Responsiveness to Immune Checkpoint Inhibitors versus Other Systemic Therapies in RET-Aberrant Malignancies. ESMO Open, 5.","DOI":"10.1136\/esmoopen-2020-000799"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.lungcan.2018.07.044","article-title":"Rare Targetable Drivers (RTDs) in Non-Small Cell Lung Cancer (NSCLC): Outcomes with Immune Check-Point Inhibitors (ICPi)","volume":"124","author":"Dudnik","year":"2018","journal-title":"Lung Cancer"},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Zhang, L., Liu, H., Tian, Y., Wang, H., and Yang, X. (2021). A Novel NCOR2-NTRK1 Fusion Detected in a Patient of Lung Adenocarcinoma and Response to Larotrectinib: A Case Report. BMC Pulm. Med., 21.","DOI":"10.1186\/s12890-021-01490-x"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1158\/1078-0432.CCR-19-3165","article-title":"TRK Fusions Are Enriched in Cancers with Uncommon Histologies and the Absence of Canonical Driver Mutations","volume":"26","author":"Rosen","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_38","first-page":"1","article-title":"The Impact of Driver Mutation on the Treatment Outcome of Early-Stage Lung Cancer Patients Receiving Neoadjuvant Immunotherapy and Chemotherapy","volume":"12","author":"Su","year":"2022","journal-title":"Sci. Rep."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"586596","DOI":"10.3389\/fonc.2020.586596","article-title":"Neoadjuvant EGFR-TKI Therapy for EGFR-Mutant NSCLC: A Systematic Review and Pooled Analysis of Five Prospective Clinical Trials","volume":"10","author":"Sun","year":"2021","journal-title":"Front. Oncol."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Dong, Z.Y., Zhang, J.T., Liu, S.Y., Su, J., Zhang, C., Xie, Z., Zhou, Q., Tu, H.Y., Xu, C.R., and Yan, L.X. (2017). EGFR Mutation Correlates with Uninflamed Phenotype and Weak Immunogenicity, Causing Impaired Response to PD-1 Blockade in Non-Small Cell Lung Cancer. Oncoimmunology, 6.","DOI":"10.1080\/2162402X.2017.1356145"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"745859","DOI":"10.3389\/fcell.2021.745859","article-title":"The Effect of Smoking on the Immune Microenvironment and Immunogenicity and Its Relationship with the Prognosis of Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer","volume":"9","author":"Sun","year":"2021","journal-title":"Front. Cell Dev. Biol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.annonc.2019.11.015","article-title":"Clinical Activity of Programmed Cell Death 1 (PD-1) Blockade in Never, Light, and Heavy Smokers with Non-Small-Cell Lung Cancer and PD-L1 Expression \u226550","volume":"31","author":"Gainor","year":"2020","journal-title":"Ann. Oncol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.3389\/fimmu.2017.01679","article-title":"Neoantigens Generated by Individual Mutations and Their Role in Cancer Immunity and Immunotherapy","volume":"8","author":"Efremova","year":"2017","journal-title":"Front. Immunol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13000-020-0927-9","article-title":"Targeted Literature Review on Use of Tumor Mutational Burden Status and Programmed Cell Death Ligand 1 Expression to Predict Outcomes of Checkpoint Inhibitor Treatment","volume":"15","author":"Krieger","year":"2020","journal-title":"Diagn. Pathol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1093\/annonc\/mdz077","article-title":"Severe Immune-Related Adverse Events Are Common with Sequential PD-(L)1 Blockade and Osimertinib","volume":"30","author":"Schoenfeld","year":"2019","journal-title":"Ann. Oncol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.jtho.2018.09.001","article-title":"Brief Report: Increased Hepatotoxicity Associated with Sequential Checkpoint Inhibitor and Crizotinib Therapy in Patients with Non-Small-Cell Lung Cancer","volume":"14","author":"Lin","year":"2019","journal-title":"J. Thorac. Oncol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"101978","DOI":"10.1016\/j.ctrv.2020.101978","article-title":"KRAS as a Druggable Target in NSCLC: Rising like a Phoenix after Decades of Development Failures","volume":"85","author":"Friedlaender","year":"2020","journal-title":"Cancer Treat. Rev."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1158\/2159-8290.CD-14-1236","article-title":"Co-Occurring Genomic Alterations Define Major Subsets of KRAS\u2013Mutant Lung Adenocarcinoma with Distinct Biology, Immune Profiles, and Therapeutic Vulnerabilities","volume":"5","author":"Skoulidis","year":"2015","journal-title":"Cancer Discov."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1056\/NEJMoa2103695","article-title":"Sotorasib for Lung Cancers with KRAS p.G12C Mutation","volume":"384","author":"Skoulidis","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1007\/s10555-020-09903-9","article-title":"Current Therapy of KRAS-Mutant Lung Cancer","volume":"39","author":"Ghimessy","year":"2020","journal-title":"Cancer Metastasis Rev."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1056\/NEJMoa2204619","article-title":"Adagrasib in Non\u2013Small-Cell Lung Cancer Harboring a KRAS G12C Mutation","volume":"387","author":"Riely","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1093\/annonc\/mdw436","article-title":"Whole-Exome Sequencing and Immune Profiling of Early-Stage Lung Adenocarcinoma with Fully Annotated Clinical Follow-Up","volume":"28","author":"Kadara","year":"2017","journal-title":"Ann. Oncol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"3012","DOI":"10.1158\/1078-0432.CCR-16-2554","article-title":"Potential Predictive Value of TP53 and KRAS Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma","volume":"23","author":"Dong","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"2828","DOI":"10.1158\/2159-8290.CD-20-1543","article-title":"Resistance to Durvalumab and Durvalumab plus Tremelimumab Is Associated with Functional STK11 Mutations in Patients with Non\u2013Small Cell Lung Cancer and Is Reversed by STAT3 Knockdown","volume":"11","author":"Pore","year":"2021","journal-title":"Cancer Discov."},{"key":"ref_55","unstructured":"(2022, August 11). Sotorasib Activity in Subjects with Advanced Solid Tumors with KRAS p.G12C Mutation (CodeBreak 101)\u2013Full Text View\u2013ClinicalTrials.Gov, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04185883."},{"key":"ref_56","unstructured":"(2022, August 10). Phase 2 Trial of MRTX849 Monotherapy and in Combination with Pembrolizumab for NSCLC with KRAS G12C Mutation KRYSTAL-7\u2013Full Text View\u2013ClinicalTrials.Gov, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04613596."},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Chen, D., Zhang, L.Q., Huang, J.F., Liu, K., Chuai, Z.R., Yang, Z., Wang, Y.X., Shi, D.C., Liu, Q., and Huang, Q. (2014). BRAF Mutations in Patients with Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0101354"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"9017","DOI":"10.1200\/JCO.2016.34.15_suppl.9017","article-title":"Total Mutation Burden (TMB) in Lung Cancer (LC) and Relationship with Response to PD-1\/PD-L1 Targeted Therapies","volume":"34","author":"Spigel","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"21","DOI":"10.2147\/LCTT.S235102","article-title":"Recognizing Prognostic and Predictive Biomarkers in the Treatment of Non-Small Cell Lung Cancer (NSCLC) with Immune Checkpoint Inhibitors (ICIs)","volume":"12","author":"Giustini","year":"2021","journal-title":"Lung Cancer Targets Ther."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1001\/jama.2019.3241","article-title":"Association of Patient Characteristics and Tumor Genomics with Clinical Outcomes Among Patients with Non-Small Cell Lung Cancer Using a Clinicogenomic Database","volume":"321","author":"Singal","year":"2019","journal-title":"JAMA"},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Amatu, A., Sartore-Bianchi, A., Bencardino, K., Pizzutilo, E.G., Tosi, F., and Siena, S. (2019). Tropomyosin Receptor Kinase (TRK) Biology and the Role of NTRK Gene Fusions in Cancer. Ann. Oncol., 30.","DOI":"10.1093\/annonc\/mdz383"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.3389\/fimmu.2019.01398","article-title":"Tertiary Lymphoid Organs in Cancer Immunology: Mechanisms and the New Strategy for Immunotherapy","volume":"10","author":"Lin","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"9065","DOI":"10.1200\/JCO.2022.40.16_suppl.9065","article-title":"Artificial Intelligence in Digital Pathology Approach Identifies the Predictive Impact of Tertiary Lymphoid Structures with Immune-Checkpoints Therapy in NSCLC","volume":"40","author":"Rakaee","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"5710","DOI":"10.1158\/1078-0432.CCR-18-0163","article-title":"TP53, STK11, and EGFR Mutations Predict Tumor Immune Profile and the Response to Anti\u2013PD-1 in Lung Adenocarcinoma","volume":"24","author":"Biton","year":"2018","journal-title":"Clin. Cancer Res."}],"container-title":["Cells"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4409\/11\/20\/3280\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:56:44Z","timestamp":1760144204000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4409\/11\/20\/3280"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,18]]},"references-count":64,"journal-issue":{"issue":"20","published-online":{"date-parts":[[2022,10]]}},"alternative-id":["cells11203280"],"URL":"https:\/\/doi.org\/10.3390\/cells11203280","relation":{},"ISSN":["2073-4409"],"issn-type":[{"value":"2073-4409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,18]]}}}